Abstract
Although luteolin is identified as a potential cancer therapeutic and preventive agent because of its potent cancer cell-killing activity, the molecular mechanisms by which its cancer cell cytotoxicity is achieved have not been well elucidated. In this report, luteolin-induced cellular signaling was systematically investigated, and a novel pathway for luteolin's lung cancer killing was identified. The results show that induction of superoxide is an early and crucial step for luteolin-induced apoptotic and nonapoptotic death in lung cancer cells. The c-Jun N-terminal kinase (JNK) was potently activated after superoxide accumulation. Suppression of superoxide completely blocked luteolin-induced JNK activation, which was well correlated to alleviation of luteolin's cytotoxicity. Although luteolin slightly stimulated the JNK-activating kinase mitogen-activated protein kinase kinase 7, the latter was not dependent on superoxide. We further found that luteolin triggers a superoxide-dependent rapid degradation of the JNK-inactivating phosphatase mitogen-activated protein kinase phosphatase-1 (MKP-1). Introduction of a degradation-resistant MKP-1 mutant effectively attenuated luteolin-induced JNK activation and cytotoxicity, suggesting that inhibition of the JNK suppressor MKP-1 plays a major role in luteolin-induced lung cancer cell death. Taken together, our results unveil a novel pathway consisting of superoxide, MKP-1, and JNK for luteolin's cytotoxicity in lung cancer cells, and manipulation of this pathway could be a useful approach for applying luteolin for lung cancer prevention and therapy.
Footnotes
This work was supported in part by the National Institutes of Health National Cancer Institute [Grant R03-CA125796] and Department of Energy Low Dose Radiation Research Program [Grant DE-SC0001173].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
ABBREVIATIONS:
- ROS
- reactive oxygen species
- TNF
- tumor necrosis factor
- NF-κB
- nuclear factor κB
- JNK
- c-Jun N-terminal kinase
- MKP-1
- mitogen-activated protein kinase phosphatase
- BHA
- butylated hydroxyanisol
- z-VAD
- N-benzyloxycarbonyl-Val-Ala-Asp(O-Met)
- NAC
- N-acetylcysteine
- SP600125
- 1,9-pyrazoloanthrone
- SB203580
- 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole
- ERK
- extracellular signal-regulated kinase
- U0126
- 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene
- IKK
- IκB kinase complex
- Ro 31-9549
- 2-[1-3-(aminopropyl)indol-3-yl]-3-(1-methyl-1H-indol-3-yl) maleimide
- Gö6976
- 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole
- MG132
- N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal
- MKK
- mitogen-activated protein kinase kinase
- DHE
- dihydroethidium
- PCR
- polymerase chain reaction
- MAPKKK
- mitogen-activated protein kinase kinase kinase
- MAPKK
- mitogen-activated protein kinase kinase
- CHX
- cycloheximide.
- Received November 2, 2011.
- Accepted January 5, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|